Founded in 2014, the company develops and commercializes products based on a proprietary nanofiber-based platform - the Cellevat3d™ - a breakthrough and green deep-tech innovation for biopharmaceutical manufacturing. This platform represents a significant advance in biopharmaceutical manufacturing due to its sustainability and efficiency.

The Cellevat3d™ platform enables large-scale production of nanofiber materials called "carriers". These carrier materials provide an unprecedented surface area for cell growth, leading to improved reproducibility and customization of bioproduction processes. This innovation has the potential to significantly improve the productivity and cost-effectiveness of bioproduction processes. Cellevat3d™ carriers are designed to integrate seamlessly with upstream bioprocessing solutions, from laboratory testing of cell lines to pilot and large-scale production of various biologic therapies. These include cell- and gene-based therapies as well as vaccines. The platform has the potential to revolutionize the entire upstream bioprocessing pipeline, from R&D to commercial manufacturing. The Cellevat3d™ microcarriers create extracellular-like environments with exceptional surfaces for adherent cell cultures. Early results suggest that they could significantly increase yields, reduce risks and lower costs in biopharmaceutical development and manufacturing. In addition, Cellevat3d™ microcarriers contribute to more sustainable and environmentally friendly bioprocessing by replacing plastic culture ware with cellulose-based materials.